{
  "id": "5c7034ae7c78d69471000063",
  "type": "list",
  "question": "List drugs included in the TRIUMEQ pill.",
  "ideal_answer": "Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
    "http://www.ncbi.nlm.nih.gov/pubmed/28748198",
    "http://www.ncbi.nlm.nih.gov/pubmed/27912079",
    "http://www.ncbi.nlm.nih.gov/pubmed/27530904",
    "http://www.ncbi.nlm.nih.gov/pubmed/29059031",
    "http://www.ncbi.nlm.nih.gov/pubmed/25395816",
    "http://www.ncbi.nlm.nih.gov/pubmed/29533918",
    "http://www.ncbi.nlm.nih.gov/pubmed/29796595"
  ],
  "snippets": [
    {
      "text": "A patient with human immunodeficiency virus-1 infection presented with sub-acute liver failure, temporally related to commencement of an antiretroviral therapy regimen containing dolutegravir (Triumeq).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059031",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Newer STRs include dolutegravir (DTG)/lamivudine (3TC)/abacavir (ABC) (Triumeq; Viiv Healthcare, Research Triangle Park, NC), rilpivirine (RPV)/emtricitabine (FTC)/tenofovir alafenamide (TAF) (Odefsey; Gilead, Foster City, CA), RPV/FTC/tenofovir disoproxil fumarate (TDF) (Complera; Gilead), elvitegravir (EVG)/cobicistat (COBI)/FTC/TDF (Stribild; Gilead), and EVG/COBI/FTC/TAF (Genvoya; Gilead). Recently approved FDCs, such as atazanavir (ATV)/COBI (Evotaz; Bristol-Myers Squibb, Princeton, NJ), darunavir (DRV)/COBI (Prezcobix; Janssen Products, Titusville NJ), and FTC/TAF (Descovy; Gilead), are also now available. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29533918",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine. Overdoses with Triumeq have not been reported previously. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29533918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there is no information about crushing of the branded fixed-dose combination of dolutegravir/abacavir/lamivudine (Triumeq\u00ae, referred to as TRI); therefore, crushing of TRI is not recommended.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29796595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On running short of medication, he admitted to sharing his partner's treatment (Triumeq; abacavir, lamivudine and dolutegravir). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27530904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Abacavir/Dolutegravir/Lamivudine (Triumeq)-Induced Liver Toxicity in a Human Immunodeficiency Virus-Infected Patient.Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748198",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Abacavir/Dolutegravir/Lamivudine (Triumeq)-Induced Liver Toxicity in a Human Immunodeficiency Virus-Infected Patient.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748198",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "On running short of medication, he admitted to sharing his partner's treatment (Triumeq; abacavir, lamivudine and dolutegravir).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27530904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Naltrexone/bupropion (Contrave) for weight management; pembrolizumab (Keytruda) for melanoma; dolutegravir/abacavir/lamivudine (Triumeq) for HIV-1; and immune globulin infusion 10% (human) with recombinant human hyaluronidase (Hyqvia) for primary immunodeficiency.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395816",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we evaluated humanized mice for their susceptibility to HIV-2 infection and tested a single-pill three drug formulation of anti-retrovirals (NRTIs abacavir and lamivudine, integrase inhibitor dolutegravir) (trade name, Triumeq<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27912079",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "dolutegravir, abacavir, lamivudine"
}